Mucosal ablation in Barrett's esophagus.
Barrett's esophagus is a prevalent, premalignant condition affecting the gastroesophageal junction and distal esophagus. Ablation plus antireflux therapy has recently been advocated to prevent the development of adenocarcinoma or to treat those unfit or unwilling to undergo esophagectomy. The present article, based on a search of Medline/ISI databases and cross-referencing of relevant articles, reviews the literature on this subject. A number of techniques have been used to remove the affected mucosa, including laser, electrocoagulation, argon plasma coagulation and photodynamic therapy but, as yet, none has been shown to be superior. Depending on the method used, ablation results in complete removal of Barrett's esophagus in approximately one third of patients and a partial response in nearly two-thirds. The resultant squamous mucosa is apparently 'normal' but may regress. To promote and maintain regeneration, antireflux therapy must be sufficient to reduce repetitive injury to the esophageal mucosa. Whether ablation reduces the cancer risk or delays its occurrence is unknown, though recent data suggests benefit. Complications are infrequent and usually mild. Regular follow-up endoscopy and deep biopsies continue to be necessary. Careful data from much larger populations with long-term follow-up is required before ablation reaches the stage of broad clinical application.
Walker
S J
SJ
Blackpool Victoria Hospital NHS Trust, Blackpool, UK. stevenjwalker@ntlworld.com
Selvasekar
C R
CR
Birbeck
N
N
D000818:Animals; D001471:Barrett Esophagus / Q000473:pathology / Q000628:therapy*; D002986:Clinical Trials as Topic; D004285:Dogs; D004564:Electrocoagulation / Q000379:methods; D004938:Esophageal Neoplasms / Q000517:prevention & control*; D004945:Esophagoscopy / Q000379:methods*; D005260:Female; D006801:Humans; D053685:Laser Therapy / Q000379:methods*; D008297:Male; D009092:Mucous Membrane / Q000473:pathology / Q000601:surgery; D010778:Photochemotherapy / Q000379:methods; D011379:Prognosis; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D016896:Treatment Outcome